Bohen Sean's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Nov 22, 2023
- Accession no.
- 0001415889-23-015456
- Filed
- Nov 22, 2023
- Trade date
- Nov 20-22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $824.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bohen SeanCIK 0001831218 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2023 | Common Stock | AGrant or awardAcquired | +110,250 | $0.00 | $0 | 202,150 | Direct | |
| Nov 21, 2023 | Common Stock | SSaleDisposed | −26,691 | $14.84 | −$396,094.44 | 175,459 | Direct | |
| Nov 21, 2023 | Common Stock | SSaleDisposed | −2,602 | $15.29 | −$39,784.58 | 172,857 | Direct | |
| Nov 22, 2023 | Common Stock | SSaleDisposed | −27,932 | $13.90 | −$388,254.8 | 144,925 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.